Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H28N2O3 |
| Molecular Weight | 392.4907 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C3=CC=C(O)C4=C3C=CC(=O)N4
InChI
InChIKey=QZZUEBNBZAPZLX-QFIPXVFZSA-N
InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1
| Molecular Formula | C24H28N2O3 |
| Molecular Weight | 392.4907 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study. | 2007 Dec |
|
| New approaches to managing asthma: a US perspective. | 2008 Apr |
|
| Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study. | 2008 Dec |
|
| Gateways to clinical trials. | 2008 Jan-Feb |
|
| Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma. | 2008 Jul |
|
| A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. | 2008 Jul |
|
| Gateways to clinical trials. | 2008 May |
|
| A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors. | 2008 Nov-Dec |
|
| Gateways to clinical trials. | 2008 Oct |
|
| Novel long-acting bronchodilators for COPD and asthma. | 2008 Oct |
|
| Gateways to clinical trials. | 2009 Apr |
|
| Bronchodilator effects of indacaterol and formoterol in patients with COPD. | 2009 Dec |
|
| Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder. | 2009 Dec |
|
| Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? | 2009 Dec 8 |
|
| 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. | 2009 Feb |
|
| Gateways to clinical trials. | 2009 Jan-Feb |
|
| Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases. | 2009 Jul |
|
| Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist. | 2009 Mar 12 |
|
| Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma. | 2009 May |
|
| 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol. | 2009 Oct |
|
| Gateways to clinical trials. | 2009 Sep |
|
| Pharmacogenetic characterization of indacaterol, a novel beta 2-adrenoceptor agonist. | 2009 Sep |
|
| The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. | 2009 Sep |
|
| [Efficacy and safety of indacaterol - new long-acting beta(2) agonist]. | 2010 |
|
| Impact of bronchodilator therapy on exercise tolerance in COPD. | 2010 Apr 7 |
|
| Indacaterol maleate for the treatment of chronic obstructive pulmonary disease. | 2010 Aug |
|
| Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. | 2010 Dec |
|
| QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. | 2010 Dec |
|
| Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. | 2010 Dec |
|
| Indacaterol: in chronic obstructive pulmonary disease. | 2010 Dec 3 |
|
| Novel bronchodilators in asthma. | 2010 Jan |
|
| Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. | 2010 Jul 15 |
|
| Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. | 2010 Jun |
|
| Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. | 2010 Jun |
|
| Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist. | 2010 Jun 15 |
|
| Indacaterol for chronic obstructive pulmonary disease (COPD). | 2010 Mar |
|
| The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. | 2010 Mar |
|
| Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. | 2010 Mar 8 |
|
| The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. | 2010 May 13 |
|
| Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. | 2010 Nov |
|
| 24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol. | 2010 Nov |
|
| [Indacaterol is a new once-daily beta2-agonist for treatment of COPD]. | 2010 Nov 22 |
|
| Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. | 2010 Oct 29 |
|
| Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. | 2010 Oct 5 |
|
| Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists. | 2010 Sep |
|
| Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial. | 2010 Sep |
|
| Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. | 2010 Sep 7 |
|
| An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol. | 2012 Oct 1 |
|
| Metabolism and pharmacokinetics of indacaterol in humans. | 2012 Sep |
|
| Emerging Therapeutic Options for the Management of COPD. | 2013 |
Sample Use Guides
The recommended dosage of Indacaterol is the once-daily inhalation of the contents of one 75 mcg Indacaterol capsule using the NEOHALER inhaler.
Route of Administration:
Respiratory
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Oct 21 23:49:38 UTC 2019
by
admin
on
Mon Oct 21 23:49:38 UTC 2019
|
| Record UNII |
8OR09251MQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QR03AC18
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
||
|
NDF-RT |
N0000175779
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
||
|
EMA ASSESSMENT REPORTS |
XOTERNA BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
||
|
NCI_THESAURUS |
C48149
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
||
|
EMA ASSESSMENT REPORTS |
ULTIBRO BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
||
|
WHO-ATC |
R03AC18
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
||
|
WHO-ATC |
R03AL04
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
||
|
WHO-VATC |
QR03AL04
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
M6240
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
PRIMARY | Merck Index | ||
|
312753-06-3
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
PRIMARY | |||
|
8457
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
PRIMARY | |||
|
DB05039
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
PRIMARY | |||
|
INDACATEROL
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
PRIMARY | |||
|
312753-06-3
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
PRIMARY | |||
|
6918554
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
PRIMARY | |||
|
CHEMBL1095777
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
PRIMARY | |||
|
1114326
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
PRIMARY | RxNorm | ||
|
7455
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
PRIMARY | |||
|
312753-06-3
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
PRIMARY | |||
|
C81644
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
PRIMARY | |||
|
SUB30138
Created by
admin on Mon Oct 21 23:49:38 UTC 2019 , Edited by admin on Mon Oct 21 23:49:38 UTC 2019
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
SHORT-ACTING
|
||
|
TRANSPORTER -> SUBSTRATE |
In vitro investigations indicated that indacaterol is a low affinity substrate for the efflux pump P-gp.
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
EXCRETED UNCHANGED |
FECAL
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | PHARMACOKINETIC |
|
|
|||
| Volume of Distribution | PHARMACOKINETIC |
|
INTRAVENOUS INFUSION |
|
||
| Tmax | PHARMACOKINETIC |
|
SINGLE OR REPEATED INHALED DOSES |
|
||